Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 9/20 | 0.34 |
| ▸ | HTR2A | P28223 | 8/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29365816 | 1.00 | HTR2C (0.34) | HTR2CHTR2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL22824053 | 0.80 | MTNR1A (0.40) | KMT2ACXCR3 | |
| SCHEMBL29365568 | 0.80 | MTNR1A (0.40) | KMT2ACXCR3 | |
| SCHEMBL16591995 | 0.77 | MAPT (0.45) | KMT2A | |
| SCHEMBL24334961 | 0.72 | KMT2A (0.48) | KMT2A | |
| SCHEMBL30424558 | 0.72 | KMT2A (0.48) | KMT2A | |
| SCHEMBL15156838 | 0.71 | KMT2A (0.47) | KMT2ACXCR3 | |
| SCHEMBL31469695 | 0.71 | HTR2A (0.37) | HTR2CHTR2AHTR2B | |
| SCHEMBL24334801 | 0.71 | MTNR1A (0.39) | KMT2A | |
| SCHEMBL23756032 | 0.71 | HTR7 (0.36) | KMT2ACXCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3983384-B1 | N-(PHENYL)-INDOLE-3-SULFONAMIDE DERIVATIVES AND RELATED COMPOUNDS AS GPR17 MODULATORS FOR TREATING CNS DISORDERS SUCH AS MULTIPLE SCLEROSIS | UCB PHARMA GMBH (DE) | 2023-10-11 | — | — | EP | disclosed |
| WO-2020254289-A1 | N-(PHENYL)-INDOLE-3-SULFONAMIDE DERIVATIVES AND RELATED COMPOUNDS AS GPR17 MODULATORS FOR TREATING CNS DISORDERS SUCH AS MULTIPLE SCLEROSIS | UCB PHARMA GMBH (DE) | 2020-12-24 | — | — | WO | disclosed |